LaBossiere of Cummings Properties negotiates 10,600 s/f lease for Excelimmune
June 10, 2009 - Front Section
Excelimmune, Inc., a biotech company that is developing novel therapies using human recombianant polyclonal antibodies, recently signed a lease for more than 10,600 s/f at 12 Cabot Rd., which is owned by Cummings Foundation, Inc. and managed by Cummings Properties, LLC. Excelimmune is relocating from Cambridge.
CSO Vincent Coljee, Ph.D. and CEO Quinton Zondervan founded Excelimmune in 2006 in Cambridge. Dr. Coljee is a Fellow at Harvard University and has served as a long-time consultant to Harvard's Physics Department. Zondervan is a veteran software entrepreneur and executive.
Zondervan said, "We are excited about the opportunity to grow our company and to provide our employees with a safe and effective space to perform their work."
"The move to Woburn nearly doubles Excelimmune's previous space, providing plenty of room for the company to expand," said Cummings Properties' leasing agent Robb LaBossiere. "Excelimmune did look at other options, but our ability to quickly deliver a clean, attractive space at a very reasonable rate were the deciding factors to lease with us," he said.
"Cummings Properties' unique design/build/lease structure, with in-house architectural, purchasing, design, construction and leasing departments, can solve complicated issues more quickly than some larger commercial real estate developers," LaBossiere said. "Excelimmune required space modifications in an extremely short amount of time, and our team could expedite the changes to meet its deadline. This lease does take a significant piece of lab space off the market."
LaBossiere represented Cummings Properties in the lease negotiations with Excelimmune.
Cummings Foundation owns several other buildings nearby, which are all strategically located minutes away from I-93, I-95/Rte. 128 and the Anderson MBTA station with Logan Express service. Other life sciences and high tech firms in these buildings include Calloway Laboratories, Thermo Fisher Scientific, BioVex and CRX.